Drug intelligence / Profile preview

CPX-351 + glasdegib

Development stage: Unknown
Lead developer: Jazz Pharmaceuticals
Modality: Small Molecules, Stealth (PEGylated) Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous (CPX-351), Oral (glasdegib)

Overview

CPX-351 + glasdegib is a combination regimen under investigation for the treatment of acute myeloid leukemia (AML), especially therapy-related AML and AML with myelodysplasia-related changes. CPX-351 is a liposomal encapsulation of cytarabine and daunorubicin in a 5:1 molar ratio, designed to enhance the synergistic cytotoxic effect and improve drug delivery to leukemic cells. Glasdegib is a small molecule inhibitor of the smoothened (SMO) receptor, a component of the Hedgehog signaling pathway, which is implicated in leukemia stem cell survival and resistance to chemotherapy. The combination aims to enhance anti-leukemic activity by combining intensive chemotherapy with targeted inhibition of leukemia stem cell survival, potentially improving outcomes in high-risk AML subgroups.

Brand names: VyxeosDaurismo
Other names: CPX-351 + glasdegibVyxeos + Daurismoliposomal cytarabine and daunorubicin + glasdegib

Targets

DNA polymerase familySMO (Smoothened)TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on CPX-351 + glasdegib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPX-351 + glasdegib.

Explore the full profile